China NMPA Approved the IND Application for New Glutamate Modulator Troriluzole, Signalling Fresh Hope for OCD Patients
/PRNewswire/ -- BioShin Limited announced today that Chinas National Medical Products Administration (NMPA) has approved the investigational new drug (IND)...
International Multi Center Phase China National Medical Products Administration U Biohaven Pharmaceuticals Inc Bioshin Limited National Medical Products Administration
Source: prnewswire.com